thiamine has been researched along with Delirium of Mixed Origin in 22 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
Excerpt | Relevance | Reference |
---|---|---|
"To determine if high dose intravenous (IV) thiamine can prevent delirium during hospitalization following allogeneic HSCT." | 9.41 | A randomized double-blind placebo-controlled trial of intravenous thiamine for prevention of delirium following allogeneic hematopoietic stem cell transplantation. ( Chien, SA; Deal, AM; Heiling, HM; McCabe, SD; Nakamura, ZM; Park, EM; Quillen, LJ; Rosenstein, DL; Shea, TC; Stanton, KE; Wood, WA, 2021) |
"The primary objective of this clinical trial is to determine if high dose IV thiamine can prevent delirium in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of cancer." | 9.34 | Design of a randomized placebo controlled trial of high dose intravenous thiamine for the prevention of delirium in allogeneic hematopoietic stem cell transplantation. ( Chien, SA; Deal, AM; Nakamura, ZM; Park, EM; Quillen, LJ; Rosenstein, DL; Shea, TC; Wood, WA, 2020) |
"gov databases were searched using relevant keywords that focus on the use of thiamine to prevent or treat delirium in critically ill patients." | 9.12 | Delirium in Critical Illness Patients and the Potential Role of Thiamine Therapy in Prevention and Treatment: Findings from a Scoping Review with Implications for Evidence-Based Practice. ( Friganovic, A; Krupa, S; Lange, S; Mędrzycka-Dąbrowska, W; Oomen, B, 2021) |
"To compare the prevalence of delirium among ICU patients who received thiamine with those who did not and to compare morbidity and mortality." | 8.31 | Thiamine Administration and the Prevalence of Delirium in the Intensive Care Unit: A Retrospective Before and After Interventional Study. ( Dana, E; Dichtwald, S; Fredman, B; Ifrach, N; Varbarbut, N; Zohar, E, 2023) |
"This review will provide evidence for the effectiveness of parental thiamine in the prevention or treatment of delirium in critical care." | 7.96 | Parenteral thiamine for prevention and treatment of delirium in critically ill adults: a systematic review protocol. ( Blackwood, B; McAuley, DF; McKenzie, CA; Ostermann, M; Page, VJ; Spronk, PE; Strain, WD; Taylor, D, 2020) |
"Thiamine deficiency (TD) is recognized in various kinds of disease with associated loss of appetite including cancer; however, TD has not been recognized in the family caregivers of cancer patients to date." | 7.91 | Thiamine deficiency observed in a cancer patient's caregiver. ( Akechi, T; Ebihara, Y; Furuya, D; Ishida, M; Onishi, H; Sato, I; Takahashi, T; Uchida, N, 2019) |
" Given the low risk and cost of BAL testing and thiamine prophylaxis and the high cost of delirium, standard protocols for prophylaxis are essential." | 7.80 | Prevention of delirium in trauma patients: are we giving thiamine prophylaxis a fair chance? ( Ball, CG; Blackmore, C; Kirkpatrick, AW; Niven, D; Ouellet, JF, 2014) |
"Thiamine is an essential cofactor in the process of nucleic acid synthesis." | 5.62 | Case of hypoactive delirium precipitated by thiamine deficiency. ( Hetzel, F; Husnain, MG; Stiff, KM; Truong, T, 2021) |
"To determine if high dose intravenous (IV) thiamine can prevent delirium during hospitalization following allogeneic HSCT." | 5.41 | A randomized double-blind placebo-controlled trial of intravenous thiamine for prevention of delirium following allogeneic hematopoietic stem cell transplantation. ( Chien, SA; Deal, AM; Heiling, HM; McCabe, SD; Nakamura, ZM; Park, EM; Quillen, LJ; Rosenstein, DL; Shea, TC; Stanton, KE; Wood, WA, 2021) |
"The primary objective of this clinical trial is to determine if high dose IV thiamine can prevent delirium in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of cancer." | 5.34 | Design of a randomized placebo controlled trial of high dose intravenous thiamine for the prevention of delirium in allogeneic hematopoietic stem cell transplantation. ( Chien, SA; Deal, AM; Nakamura, ZM; Park, EM; Quillen, LJ; Rosenstein, DL; Shea, TC; Wood, WA, 2020) |
"gov databases were searched using relevant keywords that focus on the use of thiamine to prevent or treat delirium in critically ill patients." | 5.12 | Delirium in Critical Illness Patients and the Potential Role of Thiamine Therapy in Prevention and Treatment: Findings from a Scoping Review with Implications for Evidence-Based Practice. ( Friganovic, A; Krupa, S; Lange, S; Mędrzycka-Dąbrowska, W; Oomen, B, 2021) |
"To compare the prevalence of delirium among ICU patients who received thiamine with those who did not and to compare morbidity and mortality." | 4.31 | Thiamine Administration and the Prevalence of Delirium in the Intensive Care Unit: A Retrospective Before and After Interventional Study. ( Dana, E; Dichtwald, S; Fredman, B; Ifrach, N; Varbarbut, N; Zohar, E, 2023) |
" Thiamine deficiency was suspected as thiamine stores in the body are depleted within about 18 days and her loss of appetite had continued for 5 months." | 4.12 | Wernicke encephalopathy in a caregiver: A serious physical issue resulting from stress in a family member caring for an advanced cancer patient. ( Hamaguchi, T; Horita, Y; Ishida, M; Mihara, Y; Onishi, H; Sato, I; Uchida, N; Yoshioka, A, 2022) |
"When delirium occurs in cancer patients undergoing home treatment, it is necessary to suspect thiamine deficiency as a potential cause, as appropriate diagnosis and treatment can prevent irreversible brain-related sequelae." | 4.02 | Wernicke encephalopathy in a lung cancer patient receiving home medical care. ( Ishida, M; Itami, K; Ito, H; Onishi, H; Onizawa, N; Sato, I; Uchida, N; Yoshioka, A, 2021) |
"This review will provide evidence for the effectiveness of parental thiamine in the prevention or treatment of delirium in critical care." | 3.96 | Parenteral thiamine for prevention and treatment of delirium in critically ill adults: a systematic review protocol. ( Blackwood, B; McAuley, DF; McKenzie, CA; Ostermann, M; Page, VJ; Spronk, PE; Strain, WD; Taylor, D, 2020) |
"Despite the absence of thiamine deficiency, whole blood thiamine was lower in patients with dementia and delirium compared to those without." | 3.91 | Blood Thiamine Level and Cognitive Function in Older Hospitalized Patients. ( Angersbach, B; Klimek, CN; Lueg, G; Pourhassan, M; Wirth, R, 2019) |
"Thiamine deficiency (TD) is recognized in various kinds of disease with associated loss of appetite including cancer; however, TD has not been recognized in the family caregivers of cancer patients to date." | 3.91 | Thiamine deficiency observed in a cancer patient's caregiver. ( Akechi, T; Ebihara, Y; Furuya, D; Ishida, M; Onishi, H; Sato, I; Takahashi, T; Uchida, N, 2019) |
"Wernicke encephalopathy (WE) is a neuropsychiatric disorder caused by thiamine deficiency." | 3.88 | Wernicke encephalopathy without delirium in patients with cancer. ( Akechi, T; Furuya, D; Ikebuchi, K; Ishida, M; Onishi, H; Taji, Y; Takahashi, T; Tanahashi, I, 2018) |
"Wernicke encephalopathy (WE) is a neuropsychiatric disorder caused by thiamine deficiency, and is sometimes overlooked because of the diversity of clinical symptoms." | 3.88 | Wernicke encephalopathy without delirium that appeared as agitation in a patient with lung cancer. ( Akechi, T; Furuya, D; Ikebuchi, K; Ishida, M; Onishi, H; Taji, Y; Takahashi, T; Uchida, N, 2018) |
" Thiamine deficiency was suspected because appetite loss had continued for 19 days since she had been admitted to hospital." | 3.83 | Early detection and successful treatment of Wernicke encephalopathy in a patient with advanced carcinoma of the external genitalia during chemotherapy. ( Akechi, T; Fujiwara, K; Ikebuchi, K; Ishida, M; Onishi, H; Taji, Y; Tanahashi, I; Toyama, H, 2016) |
" Given the low risk and cost of BAL testing and thiamine prophylaxis and the high cost of delirium, standard protocols for prophylaxis are essential." | 3.80 | Prevention of delirium in trauma patients: are we giving thiamine prophylaxis a fair chance? ( Ball, CG; Blackmore, C; Kirkpatrick, AW; Niven, D; Ouellet, JF, 2014) |
"Malignancy-associated primary thiamine deficiency has been documented in several experimental tumors, clinical case reports, and in patients with fast growing malignancies." | 3.73 | Development of Wernicke encephalopathy in a terminally ill cancer patient consuming an adequate diet: a case report and review of the literature. ( Kawanishi, C; Okuno, S; Onishi, H; Yae, S, 2005) |
"Although Wernicke encephalopathy has been reported in the oncological literature, it has not previously been reported in postoperative cancer patients." | 2.43 | Wernicke encephalopathy presented in the form of postoperative delirium in a patient with hepatocellular carcinoma and liver cirrhosis: a case report and review of the literature. ( Kawanishi, C; Onishi, H; Onose, M; Sugimasa, Y, 2005) |
"Thiamine is an essential cofactor in the process of nucleic acid synthesis." | 1.62 | Case of hypoactive delirium precipitated by thiamine deficiency. ( Hetzel, F; Husnain, MG; Stiff, KM; Truong, T, 2021) |
"Although Wernicke encephalopathy has been reported in the oncological literature, only one terminally ill cancer patient with Wernicke encephalopathy has been reported." | 1.32 | Successful treatment of Wernicke encephalopathy in terminally ill cancer patients: report of 3 cases and review of the literature. ( Kawanishi, C; Noda, K; Onishi, H; Onose, M; Saito, H; Yamada, T; Yoshida, A, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.55) | 18.2507 |
2000's | 6 (27.27) | 29.6817 |
2010's | 7 (31.82) | 24.3611 |
2020's | 8 (36.36) | 2.80 |
Authors | Studies |
---|---|
Ishida, M | 6 |
Uchida, N | 4 |
Yoshioka, A | 2 |
Sato, I | 3 |
Hamaguchi, T | 1 |
Horita, Y | 1 |
Mihara, Y | 1 |
Onishi, H | 9 |
Dichtwald, S | 1 |
Varbarbut, N | 1 |
Dana, E | 1 |
Zohar, E | 1 |
Ifrach, N | 1 |
Fredman, B | 1 |
McKenzie, CA | 1 |
Page, VJ | 1 |
Strain, WD | 1 |
Blackwood, B | 1 |
Ostermann, M | 1 |
Taylor, D | 1 |
Spronk, PE | 1 |
McAuley, DF | 1 |
Nakamura, ZM | 2 |
Deal, AM | 2 |
Rosenstein, DL | 2 |
Quillen, LJ | 2 |
Chien, SA | 2 |
Wood, WA | 2 |
Shea, TC | 2 |
Park, EM | 2 |
Truong, T | 1 |
Hetzel, F | 1 |
Stiff, KM | 1 |
Husnain, MG | 1 |
Stanton, KE | 1 |
McCabe, SD | 1 |
Heiling, HM | 1 |
Ito, H | 1 |
Itami, K | 1 |
Onizawa, N | 1 |
Lange, S | 1 |
Mędrzycka-Dąbrowska, W | 1 |
Friganovic, A | 1 |
Oomen, B | 1 |
Krupa, S | 1 |
Tanahashi, I | 2 |
Takahashi, T | 3 |
Taji, Y | 3 |
Ikebuchi, K | 3 |
Furuya, D | 3 |
Akechi, T | 4 |
Pourhassan, M | 1 |
Angersbach, B | 1 |
Lueg, G | 1 |
Klimek, CN | 1 |
Wirth, R | 1 |
Ebihara, Y | 1 |
Blackmore, C | 1 |
Ouellet, JF | 1 |
Niven, D | 1 |
Kirkpatrick, AW | 1 |
Ball, CG | 1 |
Toyama, H | 1 |
Fujiwara, K | 1 |
Ogihara, T | 1 |
Miyashita, M | 1 |
Kobayashi, M | 1 |
Sasayama, D | 1 |
Washizuka, S | 1 |
Hanihara, T | 1 |
Amano, N | 1 |
Sharma, TR | 1 |
Kavuru, B | 1 |
Iskandar, JW | 1 |
Coffman, A | 1 |
Johnson, K | 1 |
Watanabe, T | 1 |
Akiyama, K | 1 |
Kawanishi, C | 3 |
Onose, M | 2 |
Yamada, T | 1 |
Saito, H | 1 |
Yoshida, A | 1 |
Noda, K | 1 |
Haupt, M | 1 |
Yae, S | 1 |
Okuno, S | 1 |
Sugimasa, Y | 1 |
Sainte-Foie, S | 1 |
Bourhis, V | 1 |
Joly, F | 1 |
Petit-Bon, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation[NCT03263442] | Phase 2 | 66 participants (Actual) | Interventional | 2017-10-16 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time. (NCT03263442)
Timeframe: From baseline to one month post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | -0.70 |
Control | -0.09 |
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time. (NCT03263442)
Timeframe: Baseline to three months post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | -0.12 |
Control | 0.97 |
Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). The MOCA is a clinician-administered tool with scores ranging from 0 to 30. Lower scores indicate worse cognitive function. Scores ≤ 25 are considered clinically significant. Positive change scores indicate better function with time. (NCT03263442)
Timeframe: From baseline to six months post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | 0.71 |
Control | 1.54 |
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time. (NCT03263442)
Timeframe: Baseline to one month post-transplant
Intervention | T-score (Mean) |
---|---|
Intervention | -1.34 |
Control | 1.16 |
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time. (NCT03263442)
Timeframe: Baseline to three months post-transplant
Intervention | T-score (Mean) |
---|---|
Intervention | 0.93 |
Control | 0.32 |
Depression will be assessed using the Patient Reported Outcomes Measurement Information System - Depression (PROMIS-D) 8a short form. Scores for all PROMIS measures are reported on the T-score metric in which the mean=50 and standard deviation (SD) = 10 are centered on the general population means. Higher scores represent greater degrees of mood symptoms. Positive change scores indicate worse mood over time. (NCT03263442)
Timeframe: Baseline to six months post-transplant
Intervention | T-score (Mean) |
---|---|
Intervention | 0.14 |
Control | -1.66 |
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time. (NCT03263442)
Timeframe: Baseline to one month post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | 0.70 |
Control | 0.88 |
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time. (NCT03263442)
Timeframe: From baseline to three months post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | 0.69 |
Control | 0.60 |
Functional status will be measured using the Eastern Cooperative Oncology Group (ECOG) performance scale. ECOG performance status is a single question scored on a 6-point scale (range 0 to 5) with higher scores representing greater physical restriction due to illness. Negative change scores indicate better function with time. (NCT03263442)
Timeframe: Baseline to six months post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | 0.46 |
Control | 0.21 |
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time. (NCT03263442)
Timeframe: From baseline to one month post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | -7.53 |
Control | -5.69 |
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time. (NCT03263442)
Timeframe: Baseline to three months post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | -3.96 |
Control | -1.43 |
HRQOL will be assessed using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT). The FACT-BMT is a 47-item self-administered assessment which asks individuals to rate questions related to physical, social/family, emotional, and functional well-being on a 5-point Likert Scale (0, not at all to 4, very much). Scores are summed across the items, resulting in a score from 0 to 148, with higher scores indicating better quality of life. Negative change scores indicate worse HRQOL with time. (NCT03263442)
Timeframe: Baseline to six months post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | -4.36 |
Control | 0.28 |
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time. (NCT03263442)
Timeframe: Baseline to one month post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | -0.52 |
Control | 1.55 |
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time. (NCT03263442)
Timeframe: Baseline to three months post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | -1.50 |
Control | 0.83 |
Post-traumatic stress symptoms will be measured using the Post Traumatic Stress Syndrome Scale 14 (PTSS-14). The PTSS-14 is a 14-item self-administered assessment. Questions are on a 7-point Likert-type Scale (1, never to 7, always) resulting in a total score between 14 and 98. Higher scores represent a more likely diagnosis of post-traumatic stress disorder (PTSD). Positive change scores indicate worse post-traumatic stress over time. (NCT03263442)
Timeframe: Baseline to six months post-transplant
Intervention | score on a scale (Mean) |
---|---|
Intervention | 1.79 |
Control | 1.32 |
The relationship between thiamine levels at the end of the seven day administration of thiamine and the development of delirium at any point during the thirty days post-transplant or the post-transplant hospitalization, whichever comes first, will be examined. Thiamine levels (nmol/L) are presented in participants who did and did not experience delirium. (NCT03263442)
Timeframe: From end of 7-day intervention period until the development of delirium at any point during the post-transplant hospitalization up to a maximum of 30 days
Intervention | nmol/L (Mean) |
---|---|
Delirium | 115.6 |
No Delirium | 93.8 |
Delirium duration will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The maximum possible score is 32. Higher scores suggest more severe symptoms. A cut-off score of > 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. Delirium duration will be reported as number of consecutive days during which DRS > 12. (NCT03263442)
Timeframe: Assessments will occur in the week prior to transplant, then 3 times weekly post-transplant until 30 days post-transplant or discharge, whichever comes first.
Intervention | days (Mean) |
---|---|
Intervention | 2.0 |
Control | 4.4 |
Delirium incidence will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The maximum possible score is 32. Higher scores suggest more severe symptoms. A cut-off score of > 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. Delirium incidence will be defined as at least one assessment with DRS > 12. (NCT03263442)
Timeframe: Assessments will occur in the week prior to transplant, then 3 times weekly post-transplant until 30 days post-transplant or discharge, whichever comes first.
Intervention | percentage of participants (Number) |
---|---|
Intervention | 25 |
Control | 21 |
Delirium severity will be measured using the Delirium Rating Scale (DRS). The DRS is a is a 10-item, clinician-rated scale that rates the severity of delirium symptoms over a 24-hour period using all available information from the patient interview, mental status examination, medical history and tests, nursing observations, and family reports. The score ranges from 0 to 32 with higher scores reflecting more severe symptoms. A cut-off score of > 12 has been suggested to distinguish patients with delirium from patients with other neuropsychiatric disorders. The DRS medians and ranges are reported for each group at baseline and in each week of hospitalization for thiamine and placebo groups. (NCT03263442)
Timeframe: Assessments will occur in the week prior to transplant (baseline), then at least 3 times post-transplant on a weekly basis until 30 days post-transplant or discharge, whichever comes first, up to week 5
Intervention | score on a scale (Median) | |||||
---|---|---|---|---|---|---|
Baseline | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | |
Control | 4.0 | 4.67 | 5.33 | 5.17 | 6.00 | 7.50 |
Intervention | 4.0 | 4.83 | 6.50 | 6.33 | 5.50 | 20.00 |
4 reviews available for thiamine and Delirium of Mixed Origin
Article | Year |
---|---|
Delirium in Critical Illness Patients and the Potential Role of Thiamine Therapy in Prevention and Treatment: Findings from a Scoping Review with Implications for Evidence-Based Practice.
Topics: Critical Illness; Delirium; Evidence-Based Practice; Humans; Intensive Care Units; Length of Stay; T | 2021 |
[Vitamin deficiency].
Topics: Delirium; Humans; Niacin; Pellagra; Thiamine; Thiamine Deficiency; Wernicke Encephalopathy | 2003 |
[Diagnostics and treatment of delirium tremens--not caused by alcohol or other psychotropic substances].
Topics: Antipsychotic Agents; Delirium; Diagnosis, Differential; Humans; Hypnotics and Sedatives; Prognosis; | 2006 |
Wernicke encephalopathy presented in the form of postoperative delirium in a patient with hepatocellular carcinoma and liver cirrhosis: a case report and review of the literature.
Topics: Aged; Carcinoma, Hepatocellular; Delirium; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Ma | 2005 |
2 trials available for thiamine and Delirium of Mixed Origin
Article | Year |
---|---|
Design of a randomized placebo controlled trial of high dose intravenous thiamine for the prevention of delirium in allogeneic hematopoietic stem cell transplantation.
Topics: Delirium; Hematopoietic Stem Cell Transplantation; Humans; Quality of Life; Thiamine; Thiamine Defic | 2020 |
A randomized double-blind placebo-controlled trial of intravenous thiamine for prevention of delirium following allogeneic hematopoietic stem cell transplantation.
Topics: Administration, Intravenous; Delirium; Double-Blind Method; Hematopoietic Stem Cell Transplantation; | 2021 |
16 other studies available for thiamine and Delirium of Mixed Origin
Article | Year |
---|---|
Wernicke encephalopathy in a caregiver: A serious physical issue resulting from stress in a family member caring for an advanced cancer patient.
Topics: Aged; Caregivers; Delirium; Female; Humans; Neoplasms; Spouses; Thiamine; Thiamine Deficiency; Werni | 2022 |
Thiamine Administration and the Prevalence of Delirium in the Intensive Care Unit: A Retrospective Before and After Interventional Study.
Topics: Critical Illness; Delirium; Humans; Intensive Care Units; Length of Stay; Prevalence; Prospective St | 2023 |
Parenteral thiamine for prevention and treatment of delirium in critically ill adults: a systematic review protocol.
Topics: Adult; Critical Care; Critical Illness; Delirium; Humans; Multicenter Studies as Topic; Respiration, | 2020 |
Case of hypoactive delirium precipitated by thiamine deficiency.
Topics: Beriberi; Delirium; Humans; Male; Middle Aged; Thiamine; Thiamine Deficiency; Wernicke Encephalopath | 2021 |
Wernicke encephalopathy in a lung cancer patient receiving home medical care.
Topics: Aged, 80 and over; Delirium; Female; Humans; Lung Neoplasms; Thiamine; Thiamine Deficiency; Wernicke | 2021 |
Wernicke encephalopathy without delirium in patients with cancer.
Topics: Ataxia; Delirium; Female; Humans; Middle Aged; Neoplasms; Thiamine; Thiamine Deficiency; Wernicke En | 2018 |
Wernicke encephalopathy without delirium that appeared as agitation in a patient with lung cancer.
Topics: Delirium; Female; Humans; Lung Neoplasms; Middle Aged; Psychomotor Agitation; Thiamine; Thiamine Def | 2018 |
Blood Thiamine Level and Cognitive Function in Older Hospitalized Patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cognition; Cognitive Dysfunction; Cross-Section | 2019 |
Thiamine deficiency observed in a cancer patient's caregiver.
Topics: Aged, 80 and over; Caregivers; Delirium; Humans; Male; Neoplasms; Thiamine; Thiamine Deficiency | 2019 |
Prevention of delirium in trauma patients: are we giving thiamine prophylaxis a fair chance?
Topics: Adult; Aged; Alcoholism; Delirium; Diagnostic Tests, Routine; Ethanol; Female; Humans; Injury Severi | 2014 |
Early detection and successful treatment of Wernicke encephalopathy in a patient with advanced carcinoma of the external genitalia during chemotherapy.
Topics: Delirium; Drug Therapy; Feeding and Eating Disorders; Female; Humans; Middle Aged; Sleep Wake Disord | 2016 |
Use of thiamine in the treatment of post-electroconvulsive therapy delirium.
Topics: Aged; Delirium; Dysphonia; Electroconvulsive Therapy; Humans; Male; Thiamine; Vitamin B Complex | 2009 |
A case of confabulation and abnormal eye movements.
Topics: Adult; Cognition Disorders; Delirium; Eye Movements; Humans; Magnetic Resonance Imaging; Male; Neuro | 2011 |
Successful treatment of Wernicke encephalopathy in terminally ill cancer patients: report of 3 cases and review of the literature.
Topics: Aged; Delirium; Diagnosis, Differential; Female; Humans; Male; Neoplasms; Nutritional Status; Thiami | 2004 |
Development of Wernicke encephalopathy in a terminally ill cancer patient consuming an adequate diet: a case report and review of the literature.
Topics: Adrenal Cortex Neoplasms; Aged; Carcinoma; Delirium; Diagnosis, Differential; Energy Intake; Feeding | 2005 |
[Neuromyelopathy in the population of Noir-marron of Saint-Laurent du Maroni in French Guiana].
Topics: Adolescent; Adult; Ataxia; Cardiac Output, Low; Cerebellar Ataxia; Delirium; Dermatitis; Diet; Ethni | 1997 |